The issue with Samsung from a credibility standpoint is that their neck is not on the line. It is more of an option play. If CYDY goes big, then they win big. If CYDY goes belly-up, they lose almost nothing.

But BTD, BLA acceptance, major licensing deal, investment from a top tier pharma fund, -- even a top-tier pharma player on the BOD -- those will undoubtedly move the credibility needle.

(Even one mainstream publication mentioning LERO would be a big step up from what we have today).